{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:45Z","timestamp":1782841665317,"version":"3.54.5"},"reference-count":25,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Tripterygium glycoside tablets (TGTs), a traditional Chinese medicine\u2013based therapy and a type of conventional synthetic disease-modifying antirheumatic drug (csDMARD), have shown promise as a cost-effective alternative for rheumatoid arthritis (RA). However, there is limited evidence regarding the most effective combinations with other csDMARDs, such as methotrexate, leflunomide, and hydroxychloroquine. This study evaluates the 12-week efficacy and safety of TGT-based regimens in patients with moderately active RA.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to evaluate the clinical efficacy and safety of the csDMARD combination regimens mainly based on TGTs in the treatment of RA, using multicenter clinical data, and to explore the clinical characteristics of TGTs and identify the optimal combination therapy through a randomized controlled trial.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This multicenter, open-label randomized controlled trial recruited 188 participants (47 per group) from 3 hospitals. Eligible patients were stratified by study center and randomized in a 1:1:1:1 ratio to receive TGT monotherapy, TGT plus methotrexate, TGT plus leflunomide, or TGT plus hydroxychloroquine. The primary outcome was the American College of Rheumatology 20% improvement response rate. Secondary outcome measures included the Disease Activity Score-28 (DAS28) using erythrocyte sedimentation rate and DAS28 using C-reactive protein response rates, the Clinical Disease Activity Index, the Simplified Disease Activity Index, the pain visual analog scale (0 to 10 points), the patient global assessment, the medical doctor global assessment, quality of life (36-Item Short Form Health Survey), and the Health Assessment Questionnaire Disability Index. All enrolled patients were followed up every 4 weeks for a total of 12 weeks. Adverse events were recorded during the observation period of the study. All patients randomized in this study will be included in the intention-to-treat analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study was funded in February 2024. Funding was provided by the Beijing Tongzhou District Science and Technology Planning Project. Recruitment of participants commenced on September 1, 2024, and concluded on December 31, 2025. A total of 181 patients were enrolled. Final data collection has been completed, and data cleaning is currently underway. Statistical analyses have not yet been performed. The primary results are expected to be submitted for publication by the end of 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This trial uses multicenter clinical data to provide robust evidence on the efficacy and safety of TGTs in combination with csDMARDs for the treatment of RA with moderate disease activity.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/87156","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:30:06Z","timestamp":1774611006000},"page":"e87156-e87156","source":"Crossref","is-referenced-by-count":0,"title":["Tripterygium Glycoside Tablets Combined With Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Treating Rheumatoid Arthritis: Protocol for a Prospective, Multicenter, Open-Label Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-1959","authenticated-orcid":false,"given":"Liu","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5209-4027","authenticated-orcid":false,"given":"Tuoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4722-077X","authenticated-orcid":false,"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-7762","authenticated-orcid":false,"given":"Chunping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0111-7999","authenticated-orcid":false,"given":"Luming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4966-8311","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"6","key":"R1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","journal-title":"N Engl J Med"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2665-9913(25)00252-8","article-title":"The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis","volume":"8","author":"Triaille","journal-title":"Lancet Rheumatol"},{"issue":"10055","key":"R3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","journal-title":"Lancet"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"R5","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.berh.2019.101477","article-title":"The epidemiology of established rheumatoid arthritis","volume":"33","author":"Ot\u00f3n","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"R6","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s10067-024-07083-3","article-title":"Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on GBD 2021 data","volume":"43","author":"Gu","journal-title":"Clin Rheumatol"},{"issue":"4","key":"R7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/acr.22160","article-title":"Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study","volume":"66","author":"Xu","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"R8","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease study 2021","volume":"5","author":"GBD 2021 Rheumatoid Arthritis Collaborators","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"R10","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","journal-title":"Immunity"},{"issue":"7","key":"R11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/annrheumdis-2021-221841","article-title":"Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations","volume":"81","author":"Jin","journal-title":"Ann Rheum Dis"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102308","article-title":"Tapering biologic DMARDs in rheumatoid arthritis","volume":"67","author":"Braverman","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"R13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40264-024-01461-1","article-title":"A systematic overview of contraindications and special warnings for biologic and targeted synthetic disease modifying antirheumatic drugs: establishing a framework to create a \"safety checklist\"","volume":"47","author":"Skaarup","journal-title":"Drug Saf"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4450162","article-title":"Cost-effectiveness analysis of biopharmaceuticals for treating rheumatoid arthritis: infliximab, adalimumab, and etanercept","volume":"2021","author":"Gholami","journal-title":"Biomed Res Int"},{"issue":"3","key":"R15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/med.21762","article-title":"Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment","volume":"41","author":"Zhang","journal-title":"Med Res Rev"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106405","article-title":"Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: a systematic review and meta-analysis of randomized controlled trials","volume":"184","author":"Feng","journal-title":"Pharmacol Res"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103148","article-title":"2023 International Consensus Guidance for the use of Tripterygium wilfordii Hook F in the treatment of active rheumatoid arthritis","volume":"142","author":"Zhang","journal-title":"J Autoimmun"},{"issue":"10","key":"R18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1080\/03007995.2025.2580761","article-title":"Clinical characteristics of inadequate response to csDMARDs and bDMARDs in patients with rheumatoid arthritis: a cross-sectional, large cohort, real-world practice study","volume":"41","author":"Xu","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"R19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15070800","article-title":"Impact of csDMARDs vs. b\/tsDMARDs on the prognosis of rheumatoid arthritis-associated interstitial lung disease: a multicenter, retrospective study","volume":"15","author":"Lee","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"R20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","journal-title":"Arthritis Rheum"},{"issue":"9","key":"R21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","journal-title":"Arthritis Rheum"},{"issue":"6","key":"R22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"R23","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/ptr.6996","article-title":"The effectiveness and safety of Tripterygium wilfordii glycosides combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of 40 randomized controlled trials","volume":"35","author":"Zheng","journal-title":"Phytother Res"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e87156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:14:40Z","timestamp":1782839680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e87156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2196\/87156","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"v15i6e87156"}}